Police 'increasingly concerned' for missing Cole Cooper
Police are becoming "increasingly concerned" for a teenager who has been missing for three weeks.
Cole Cooper, 19, was last seen at about 20:45 on 7 May in Longcroft, Falkirk, near his home village of Banknock.
Ch Insp Alex Hatrick told BBC Scotland News Cole's disappearance was being treated as a missing persons case and there was no evidence to suggest he had come to harm.
Since the final sighting officers have conducted door-to-door inquiries at more than 200 homes and obtained over 1,000 hours of CCTV.
Members of Cole's family have told BBC Scotland News his lack of contact with them is highly unusual and they fear he has come to some kind of harm.
Ch Insp Hatrick, local area commander, told BBC Scotland News: "Just like Cole's family we are increasingly concerned for Cole's whereabouts.
"The family are obviously deeply devastated, they are looking for answers as to what has happened to Cole, as are the police.
"At this time this is very much a missing persons inquiry.
"There is no evidence to suggest Cole has come to harm but we will explore all avenues, all lines of inquiry. Our focus is very much on tracing Cole."
3 May: Cole was on a night out with friends.
4 May: He was captured on CCTV multiple times around Nisbet Drive, Longcroft Road and Hogan Path in the early hours of Sunday morning.
He was seen approaching the door of his father's house at 05:49 before leaving four minutes later.
The last CCTV footage of Cole was at 06:00 on Cumbernauld Road.
7 May: A witness said they saw Cole at around 20:45 on the A803 at the Intersection with Cumbernauld Road, Longcroft.
9 May: Cole is reported missing.
Ch Insp Hatrick said police believe the last sighting of Cole on the evening of 7 May, reported by a witness who knew him.
The witness told officers that he did not have any concerns for Cole.
He told them Cole had asked for a lift and then "went on his way".
Cole is described as about 5ft 10in, of medium build with short brown hair.
He was last seen wearing a black puffer-style jacket with black jogging bottoms.
But Cole's family are treating the earlier CCTV footage - captured on 4 May - as the last confirmed sighting of the missing teenager.
Brother Connor told BBC Radio Scotland's Drivetime programme they were hoping "no news is good news" but were becoming increasingly worried.
He said: "We are coming up to a month now which does make me think, has he come to some sort of harm?
"I don't know what type of harm but I do think that something must have happened and somebody knows something.
"We are mentally preparing for the worst but we are also hoping and praying for the best outcome which is him coming home safely."
The family organised a community-led search for the teenager on Saturday and Sunday, with around 200 people helping looking for Cole.
"We don't want to sit back and do nothing. Even if we need to search the same area a hundred more times, we will," Connor added.
Cole had been living in Falkirk and is known to have links to the Denny, Cumbernauld and Paisley areas.
A major search involving helicopters and drones was launched last week scouring Banknock, also in Falkirk, and the dive and marine unit have been involved.
Police are asking for anyone who was in the Glasgow Road area around the time Cole was last seen to contact them via an online portal.
They are also urging locals to to check their outbuildings and sheds.
Family and friends lead search for missing Falkirk teenager
'All I want is the safe return of my gorgeous, fun-loving boy'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Parents sue over son's asthma death days after inhaler price soared without warning
When 22-year-old Cole Schmidtknecht tried to get a refill on the inhaler prescribed by his doctor to prevent asthma attacks. The medication that had formerly cost him less than $70 at his Appleton, Wisconsin pharmacy was now priced at more than $500, according to Cole's father, Bil Schmidtknecht. Stunned, Cole left the store with a medication designed to stop asthma attacks once they start, but without the Advair Diskus inhaler he needed to prevent attacks from happening in the first place. Five days after his pharmacy visit last year, Cole had a severe asthma attack, stopped breathing and collapsed. He never regained consciousness and died. Doctors attributed his death to asthma. His parents, Bil and Shanon Schmidtknecht, blame what they say is a dysfunctional system where medications can change in price overnight and without notice. A part of the insurance system that many Americans don't know about was responsible for the spike in Cole's inhaler price. Pharmacy benefit managers, or PBMs, are the middlemen that control behind the scenes which drugs will be on an insurance company's list of covered medications (called its formulary). They add or subtract medications through a process that emphasizes profits for the pharmacy benefit manager by way of 'rebates' from drug makers, said Gerard Anderson, a professor of health policy and management at the Johns Hopkins University Bloomberg School of Public Health. PBMs 'are looking for the drug that makes them the most money,' Andersen said 'It's insane that it's happening in America,' Bil Schmidknecht said. 'It's not broken. It's designed to work this way. It's just hurting us.' The Schmidtknechts are pushing for legislation that would require a 90-day warning when an insurance company's formulary is changed. They are also suing Optum Rx, the PBM that took Cole's Advair Diskus off his insurance company's formulary, and Walgreens, his pharmacy, which, the Schmidtknechts say, didn't offer Cole a way to control his asthma while another solution could be found. The lawsuit claims that Cole did not get the required 30 days' notice of the change, that his doctor wasn't contacted and that the pharmacy didn't provide Cole with any more affordable options. The Schmidknechts said Cole left the pharmacy with only a rescue inhaler, which is used for quick relief. But that type of medication by itself isn't strong enough to keep someone out of the emergency room if the asthma attack is severe, Dr. David Bernstein, an immunologist who is a professor in the division of immunology, allergy and rheumatology at the University of Cincinnati, said. 'It was empty at his house, next to his bed,' Bil said of the emergency inhaler. In a motion to dismiss the Schmidkneckt's lawsuit, Optum Rx expressed 'its deepest sympathies' for Cole's death and said federal law prohibits the case from being brought in state court. Optum also said three alternatives, each with a $5 copay, were available, and its system instructed Walgreens to contact Cole's doctor about those options. Walgreens also offered 'its deepest sympathies and cited privacy for why it can't discuss specifics in the case. In a statement, it added, 'In general, in cases where a medication is not covered by insurance, pharmacy staff may work with the plan, patient, and/or prescriber in an effort to process and dispense the prescription if able.' Cole would be 24 now. When speaking about all the things he could have been doing, his parents nearly break down. 'He was just so young, and he had his whole life ahead of him,' Shanon said. 'And it was so preventable and so unnecessary.' For the Schmidkneckts, it's about policy change. 'Justice for Cole, of course, but bigger than that, justice for us all,' Shanon said. Getting that change won't be easy. In the U.S., just three PBMs process 80% of prescriptions. And a big part of the PBM formulary playbook is secrecy, Anderson said. That way, patients don't learn how PBMs make their decisions about drugs and why a medication that had been on the formulary no longer is. Often no one, from the patients to the drug companies to the insurers, is aware of the details of the decisions the PBMs are making. 'They do not share this information widely, as it is considered a trade secret,' Anderson said. The deals are 'a negotiation between the drug companies and the PBM,' Anderson said. 'The drug company wants their drug on the formulary in a favorable position. The PBM wants to get the largest possible rebate.' The 'rebate' is the difference between the list price for a drug and what the PBM can buy it for, which can be 'a very much lower number than the list price,' Anderson said. When there are multiple drugs that do essentially the same thing, then there's a bidding war, usually a silent one. The rewards for the PBMs can be huge. A Federal Trade Commission report released in January found that, over the past few years, the three biggest PBMs — CVS Health Caremark Rx, Cigna's Express Scripts and UnitedHealth Group's Optum Rx — inflated the costs of numerous life-saving medications by billions of dollars. The companies countered that the FTC report's conclusions were misleading. In January, CVS Health said in a statement that it 'is inappropriate and misleading to draw broad conclusions from cherry-picked 'specialty generic' outliers' and that the company's 'top priority is to make health care more affordable.' OptumRx said that it helped eligible patients save $1.3 billion last year and estimated that the median out-of-pocket payment for these patients was $5. To remember Cole, both his parents had a tattoo just like his inked onto their wrists. When they feel overwhelmed they glance down at it to remember the change they want to make in his honor. 'It's just everyone's little reminder, you know, from Cole to just keep living and that we can still be happy,' Shanon said. 'I keep trying to remind myself that happiness and joy and grief can co-exist.' We're reporting in depth on the systems surrounding our health care and insurance industries. If you are dealing with bills that seem to be out of line or a denial of coverage, care or repairs, whether for health, home or auto, please email us at Costofdenial@ This article was originally published on
Yahoo
17 hours ago
- Yahoo
Max Fried Has Become Yankees' Ace With Gerrit Cole Sidelined
LOS ANGELES—Despite Max Fried's loss to the Los Angeles Dodgers Friday night at Dodger Stadium, the left-hander has more than helped the Yankees overcome the absence of staff ace Gerrit Cole, who is sideline for the season with an elbow injury. Aaron Judge said he doesn't know where the Yankees would be without Fried, like Cole a Los Angeles-area native. Advertisement More from 'I knew Max was always this good from just watching him on TV with the Braves, watching them on their World Series run, what he was able to do,' Judge said before the Yanks salvaged the finale of the three-game series with Sunday's 7-3 win. 'But now watching him up close you see the total package.' Fried was supposed to give the Yankees a potent starting one-two pitching punch when he signed as a free agent this past offseason for eight year and $218 million. Cole then blew out his right elbow during spring training and had to undergo Tommy John ligament replacement surgery. He had missed nearly the first three months of the 2024 season with soreness in the same elbow. Cole's in the midst of nine-year, $324 million contract and for the Yankees this year his $36 million is dead money – salary guaranteed to a player not on the active roster. Advertisement He's gone for the season until sometime into 2026 as he rehabs from a surgery that left a scraggily scar on that elbow. He's on the trip to California and said he's still in the strength and conditioning phase of his recovery. Picking up a baseball and tossing it is still down the road. The typical rehab from his kind of surgery could take as long as 18 months. 'I'm a little bit of a pragmatic type of guy,' Cole said. 'I want to just take it a day at time, but I feel like everything is going fine right now. Part of the challenge of these long processes is not to get ahead of yourself.' Meanwhile Fried, with ample help in the starting rotation from Carlos Rodon, has more than filled the gap. He went into Friday's game with a 7-0 record and a league-leading 1.28 ERA. After a pair of Shohei Ohtani homers and a blown 5-2 lead, he took the 8-5 loss. His record fell to 7-1 and his ERA increased to 1.92, now good for fifth in the Major Leagues. Fried wasn't around last fall when the Yankees met the Dodgers in the World Series. He was still a member of the Atlanta Braves. But the results Friday night were much the same as Game 5 at Yankee Stadium when Cole was on the mound and the Yankees blew a 5-0 lead on a shoddy display of fifth-inning defense. They lost the series that night. Advertisement Judge dropped a liner to center, Anthony Volpe made a bad throw to third base, and Cole failed to cover first base on a Mookie Betts' grounder to Anthony Rizzo. Cole said that night that he would take the responsibility for the loss, but not the blame. 'I took a bad angle to the ball,' he said. 'By the time it got by me I was not in position to cover first.' With seven months and 3,000 miles separating the situations, Fried didn't feel any better Friday night and the Yankees' pitching collapsed on Saturday in a crushing, 18-2 loss. 'I thought the guys did a great job getting me an early lead,' Fried, who had forearm problems of his own last season and missed a month, said Friday night. 'I just didn't do the job. I'm a competitor and I want to go out here and win. We had a lead, and I gave it up a couple of times. It just doesn't sit well with me.' Advertisement Asked if he liked that kind of spirit from Fried, Yanks manager Aaron Boone said Saturday: 'I like everything about him.' Boone feels the same way about Judge, who continues to pound the ball in what has been an historic first two months of the season that ended on Saturday. He hit .398 with 21 homers, 50 RBIs, 86 hits, 54 runs scored, a .490 on-base percentage and a 1.268 OPS. Judge hit three first-pitch solo homers in the first two games of the Dodgers series, the type of performance of which the Yanks have become accustomed, two of them behind Fried. 'He's been doing that all season, so it's not surprising,' Fried said. Advertisement Even with Fried's first poor outing of the season, he's still has an 0.97 WHIP, 70 strikeouts in 75 innings and has allowed just 16 earned runs, 57 hits and 16 walks in his first 12 starts. Opponents are hitting .205 against him. Like Cole, Fried has World Series experience. Cole pitched for Houston twice in 2019 and split his two starts as the Astros lost in seven games to the Washington Nationals. Two years later, Fried was on the mound for the Braves against the Astros in a deciding Game 6. He pitched six innings of no-run, four hit ball in a 7-0 championship-winning effort. By that time, Cole had already signed with the Yankees. The fact that Cole went down after the Yankees signed Fried is no small consolation. 'Max has been a huge contributor to where we are right now,' Cole said. 'Aaron having the season he's had for us is always a driving force. He's really steady Eddie every day and we're lucky to have him. It's just tough for me to sit here watching it. But that's the hand I was dealt and I'm trying to play it the best I can.' Advertisement Best of Sign up for Sportico's Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.
Medscape
19 hours ago
- Medscape
Beta-Lactam Allergy De-Labeling Safe, Effective in Seniors
Beta-lactam allergy de-labeling was safe and effective for older adult patients, successfully removing false allergy labels in 87.3% of cases, with no patients requiring hospitalization or adrenaline administration. METHODOLOGY: Researchers conducted a decade-long retrospective analysis to evaluate the safety and efficacy of beta-lactam allergy evaluations in older adult patients previously labeled as allergic. The analysis included 166 older adult patients (mean age, 71 years; 72.9% women) who were evaluated between 2009 and 2019 for suspected beta-lactam allergy. All participants underwent comprehensive anamnesis, skin testing, and, when indicated, an oral challenge; those who were successfully de-labeled underwent long-term follow-up to monitor beta-lactam use and outcomes. TAKEAWAY: Beta-lactam allergy was ruled out in 87.3% of patients; 9.6% had immediate-type hypersensitivity reactions, 2.4% had severe delayed-type hypersensitivity reactions, and 0.6% experienced a benign rash. No participant required hospitalization or emergency adrenaline treatment during the evaluation. In a long-term follow-up (3-13 years) of 106 patients, 35.8% were treated with the previously suspected beta-lactam agent, and no immediate-type or severe delayed-type hypersensitivity reactions were reported. IN PRACTICE: 'Increased awareness is crucial for enhancing allergic workup in the geriatric population bearing beta-lactam allergy labels,' the authors wrote. 'We believe that establishing the removal rate of false BL [beta-lactam] allergy labels as a healthcare quality metric and making it mandatory under the supervision of health authorities will improve outcomes for both the general population and the geriatric population,' they added. SOURCE: Saray Sity-Harel, MD, with Tel-Aviv University, Tel-Aviv, Israel, was the corresponding author of the study, which was published online in Journal of Clinical Medicine . LIMITATIONS: This study had a single-center design and limited patient follow-up data, which may reduce the generalizability of the findings and the validity of the outcomes. DISCLOSURES: The authors reported having no conflicts of interest.
